Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 3/20 | 0.37 |
| ▸ | RXRB | P28702 | 3/20 | 0.37 |
| ▸ | RXRG | P48443 | 3/20 | 0.37 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 4/20 | 0.36 |
| ▸ | TDO2 | P48775 | 2/20 | 0.35 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3597970 | 0.87 | GSK3B (0.44) | GSK3BMAPTKDM4EGAAL3MBTL1 | |
| SCHEMBL3589133 | 0.82 | GSK3B (0.50) | GSK3BMAPTKDM4EGAAL3MBTL1 | |
| Hydrochloric Acid SCHEMBL5324374 | 0.75 | IDO1 (0.48) | GSK3BMAPTKDM4EGAAL3MBTL1 | |
| SCHEMBL13989289 | 0.72 | IDO1 (0.42) | GSK3BMAPTKDM4EGAAL3MBTL1 | |
| Hydrochloric Acid SCHEMBL4878833 | 0.72 | IDO1 (0.41) | GSK3BMAPTKDM4EGAAL3MBTL1 | |
| SCHEMBL13989350 | 0.72 | MAPT (0.39) | GSK3BMAPTKDM4EGAAL3MBTL1 | |
| SCHEMBL12997374 | 0.68 | MAPT (0.43) | GSK3BMAPTKDM4EGAAL3MBTL1 | |
| SCHEMBL12997365 | 0.67 | MAPT (0.39) | GSK3BMAPTKDM4EGAAL3MBTL1 | |
| SCHEMBL28648105 | 0.67 | GSK3B (0.68) | GSK3BMAPTKDM4EGAAL3MBTL1 | |
| SCHEMBL3585109 | 0.66 | PPARG (0.45) | MAPTRXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2004185-B1 | NOVEL HETEROCYCLIC DIPHENYL ETHERS | BEXEL PHARMACEUTICALS INC (US) | 2013-06-26 | — | — | EP | claimed |
| US-7781464-B2 | Heterocyclic diphenyl ethers | BEXEL PHARMACEUTICALS, INC. (US) | 2010-08-24 | — | — | US | claimed |
| EP-2004185-A2 | NOVEL HETEROCYCLIC DIPHENYL ETHERS | Bexel Pharmaceuticals Inc (US) | 2008-12-24 | — | — | EP | claimed |
| WO-2007097992-A2 | NOVEL HETEROCYCLIC DIPHENYL ETHERS | BEXEL PHARMACEUTICALS, INC. (US) | 2007-08-30 | — | — | WO | claimed |
| US-20060247285-A1 | Novel heterocyclic diphenyl ethers | BEXEL PHARMACEUTICALS, INC. | 2006-11-02 | — | — | US | claimed |
| EP-2004185-B1 | NOVEL HETEROCYCLIC DIPHENYL ETHERS | BEXEL PHARMACEUTICALS INC (US) | 2013-06-26 | — | — | EP | disclosed |
| US-7781464-B2 | Heterocyclic diphenyl ethers | BEXEL PHARMACEUTICALS, INC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-20060247285-A1 | Novel heterocyclic diphenyl ethers | BEXEL PHARMACEUTICALS, INC. | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247285-A1 | Novel heterocyclic diphenyl ethers | FFAR4, FFAR3, GPR119 | GSK3B 1877/4885MAPT 318/4885KDM4E 775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.